anlotinib + TQB2450 + albumin-bound paclitaxel

This is a **combination therapy** consisting of three agents: - **Anlotinib**: a multitargeted small-molecule tyrosine kinase inhibitor (TKI) that primarily inhibits vascular endothelial growth factor receptors (VEGFR1-3), as well as other kinases. Its mechanism includes antiangiogenic and antiproliferative activity, and it is indicated for multiple solid tumors, including non-small cell lung cancer and biliary tract cancer[7]. - **TQB2450 (benmelstobart)**: a novel humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1). By inhibiting PD-L1, TQB2450 reactivates antitumor immune responses by blocking the PD-L1/PD-1 and PD-L1/CD80 interactions, leading to enhanced T cell activation[2][5]. - **Albumin-bound paclitaxel (nab-paclitaxel)**: a cytotoxic antimicrotubule agent formulated with albumin to facilitate tumor delivery. It acts by promoting microtubule assembly and stabilization, preventing normal cell division and thereby inducing apoptosis in rapidly dividing cancer cells[3][6][9]. This regimen is being clinically evaluated for first-line treatment of advanced solid malignancies, including **esophageal squamous cell carcinoma (ESCC), biliary tract cancer, triple-negative breast cancer**, and other advanced or metastatic tumors. The combination intends to exploit immunotherapeutic activity (PD-L1 inhibition), antiangiogenic effects (VEGFR inhibition), and enhanced cytotoxicity (albumin-bound paclitaxel) for synergistic antitumor response[1][7][4].

Brand names

ABRAXANE

Other names

protein-bound paclitaxelnanoparticle albumin-bound paclitaxel